Orchard Therapeutics Plc (ORTX) Misses Q4 EPS by 1c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q4 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Five Below (FIVE) Tops Q2 EPS by 35c, Beats on Revenue; Offers Q3 Revenue Guidance
• Snowflake (SNOW) Tops Q2 EPS by 17c, Offers Guidance